Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets

Authors: Josane F Sousa, Enilza M Espreafico

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Melanoma progression occurs through three major stages: radial growth phase (RGP), confined to the epidermis; vertical growth phase (VGP), when the tumor has invaded into the dermis; and metastasis. In this work, we used suppression subtractive hybridization (SSH) to investigate the molecular signature of melanoma progression, by comparing a group of metastatic cell lines with an RGP-like cell line showing characteristics of early neoplastic lesions including expression of the metastasis suppressor KISS1, lack of αvβ3-integrin and low levels of RHOC.

Methods

Two subtracted cDNA collections were obtained, one (RGP library) by subtracting the RGP cell line (WM1552C) cDNA from a cDNA pool from four metastatic cell lines (WM9, WM852, 1205Lu and WM1617), and the other (Met library) by the reverse subtraction. Clones were sequenced and annotated, and expression validation was done by Northern blot and RT-PCR. Gene Ontology annotation and searches in large-scale melanoma expression studies were done for the genes identified.

Results

We identified 367 clones from the RGP library and 386 from the Met library, of which 351 and 368, respectively, match human mRNA sequences, representing 288 and 217 annotated genes. We confirmed the differential expression of all genes selected for validation. In the Met library, we found an enrichment of genes in the growth factors/receptor, adhesion and motility categories whereas in the RGP library, enriched categories were nucleotide biosynthesis, DNA packing/repair, and macromolecular/vesicular trafficking. Interestingly, 19% of the genes from the RGP library map to chromosome 1 against 4% of the ones from Met library.

Conclusion

This study identifies two populations of genes differentially expressed between melanoma cell lines from two tumor stages and suggests that these sets of genes represent profiles of less aggressive versus metastatic melanomas. A search for expression profiles of melanoma in available expression study databases allowed us to point to a great potential of involvement in tumor progression for several of the genes identified here. A few sequences obtained here may also contribute to extend annotated mRNAs or to the identification of novel transcripts.
Appendix
Available only for authorised users
Literature
1.
Grossman D, Altieri DC: Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev. 2001, 20 (1-2): 3-11.CrossRefPubMed
2.
Helmbach H, Rossmann E, Kern MA, Schadendorf D: Drug-resistance in human melanoma. Int J Cancer. 2001, 93 (5): 617-622.CrossRefPubMed
3.
4.
Meier F, Satyamoorthy K, Nesbit M, Hsu MY, Schittek B, Garbe C, Herlyn M: Molecular events in melanoma development and progression. Front Biosci. 1998, 3: D1005-10.CrossRefPubMed
5.
Kath R, Jambrosic JA, Holland L, Rodeck U, Herlyn M: Development of invasive and growth factor-independent cell variants from primary human melanomas. Cancer Res. 1991, 51 (8): 2205-2211.PubMed
6.
Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, Elder DE, Bondi E, Guerry D, Nowell P, Clark WH, et al: Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res. 1985, 45 (11 Pt 2): 5670-5676.PubMed
7.
Hsu MY, Elder, D. E., Herlyn, M.: Melanoma: The Wistar Melanoma (WM) Cell Lines. Human Cell Cultures. 1999, Kluwer Academic Publishers, 1: 259-274.CrossRef
8.
Hsu MY, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA, Herlyn M: Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol. 1998, 153 (5): 1435-1442.CrossRefPubMedPubMedCentral
9.
Herlyn M, Balaban G, Bennicelli J, Guerry D, Halaban R, Herlyn D, Elder DE, Maul GG, Steplewski Z, Nowell PC, et al: Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst. 1985, 74 (2): 283-289.PubMed
10.
Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, Pinnix CC, Li X, Herlyn M: Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res. 2006, 66 (8): 4182-4190.CrossRefPubMed
11.
Ryu B, Kim DS, Deluca AM, Alani RM: Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS ONE. 2007, 2 (7): e594-CrossRefPubMedPubMedCentral
12.
van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415 (6871): 530-536.CrossRefPubMed
13.
14.
Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, Naber SP, Weinberg RA: The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet. 2005, 37 (10): 1047-1054.CrossRefPubMedPubMedCentral
15.
Abramova L, Slingluff CL, Patterson JW: Problems in the interpretation of apparent "radial growth phase" malignant melanomas that metastasize. J Cutan Pathol. 2002, 29 (7): 407-414.CrossRefPubMed
16.
Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M: The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005, 102 (17): 6092-6097.CrossRefPubMedPubMedCentral
17.
Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry D, Schuchter L, Van Belle TJ, Albelda S, Tahin P, Herlyn M, Elder DE: Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol. 1999, 30 (5): 562-567.CrossRefPubMed
18.
Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA, Brooks PC: Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 1999, 59 (11): 2724-2730.PubMed
19.
Sturm RA, Satyamoorthy K, Meier F, Gardiner BB, Smit DJ, Vaidya B, Herlyn M: Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Res. 2002, 62 (1): 226-232.PubMed
20.
Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR: KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996, 88 (23): 1731-1737.CrossRefPubMed
21.
Shirasaki F, Takata M, Hatta N, Takehara K: Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3-q23. Cancer Res. 2001, 61 (20): 7422-7425.PubMed
22.
Kotani M, Detheux M, Vandenbogaerde A, Communi D, Vanderwinden JM, Le Poul E, Brezillon S, Tyldesley R, Suarez-Huerta N, Vandeput F, Blanpain C, Schiffmann SN, Vassart G, Parmentier M: The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 2001, 276 (37): 34631-34636.CrossRefPubMed
23.
Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y, Ishibashi Y, Watanabe T, Asada M, Yamada T, Suenaga M, Kitada C, Usuki S, Kurokawa T, Onda H, Nishimura O, Fujino M: Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 2001, 411 (6837): 613-617.CrossRefPubMed
24.
Lee JH, Welch DR: Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res. 1997, 57 (12): 2384-2387.PubMed
25.
Masui T, Doi R, Mori T, Toyoda E, Koizumi M, Kami K, Ito D, Peiper SC, Broach JR, Oishi S, Niida A, Fujii N, Imamura M: Metastin and its variant forms suppress migration of pancreatic cancer cells. Biochem Biophys Res Commun. 2004, 315 (1): 85-92.CrossRefPubMed
26.
Sanchez-Carbayo M, Capodieci P, Cordon-Cardo C: Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol. 2003, 162 (2): 609-617.CrossRefPubMedPubMedCentral
27.
Clark EA, Golub TR, Lander ES, Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000, 406 (6795): 532-535.CrossRefPubMed
28.
Strausberg RL, Simpson AJ, Wooster R: Sequence-based cancer genomics: progress, lessons and opportunities. Nat Rev Genet. 2003, 4 (6): 409-418.CrossRefPubMed
29.
Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED, Siebert PD: Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci U S A. 1996, 93 (12): 6025-6030.CrossRefPubMedPubMedCentral
30.
Cao W, Epstein C, Liu H, DeLoughery C, Ge N, Lin J, Diao R, Cao H, Long F, Zhang X, Chen Y, Wright PS, Busch S, Wenck M, Wong K, Saltzman AG, Tang Z, Liu L, Zilberstein A: Comparing gene discovery from Affymetrix GeneChip microarrays and Clontech PCR-select cDNA subtraction: a case study. BMC Genomics. 2004, 5 (1): 26-CrossRefPubMedPubMedCentral
31.
Silva WA, Costa MC, Valente V, Sousa JF, Paco-Larson ML, Espreafico EM, Camargo SS, Monteiro E, Holanda AJ, Zago MA, Simpson AJ, Dias Neto E: PCR template preparation for capillary DNA sequencing. Biotechniques. 2001, 30 (3): 537-540.PubMed
32.
33.
34.
35.
36.
37.
38.
Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001, 98 (9): 5116-5121.CrossRefPubMedPubMedCentral
39.
Mueller A, O'Rourke J, Grimm J, Guillemin K, Dixon MF, Lee A, Falkow S: Distinct gene expression profiles characterize the histopathological stages of disease in Helicobacter-induced mucosa-associated lymphoid tissue lymphoma. Proc Natl Acad Sci U S A. 2003, 100 (3): 1292-1297.CrossRefPubMedPubMedCentral
40.
Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998, 95 (25): 14863-14868.CrossRefPubMedPubMedCentral
41.
Woods D, Cherwinski H, Venetsanakos E, Bhat A, Gysin S, Humbert M, Bray PF, Saylor VL, McMahon M: Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol. 2001, 21 (9): 3192-3205.CrossRefPubMedPubMedCentral
42.
Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, Iida J, Simpson MA, McCarthy JB: Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol. 2004, 165 (6): 881-891.CrossRefPubMedPubMedCentral
43.
Tralhao JG, Schaefer L, Micegova M, Evaristo C, Schonherr E, Kayal S, Veiga-Fernandes H, Danel C, Iozzo RV, Kresse H, Lemarchand P: In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J. 2003, 17 (3): 464-466.PubMed
44.
Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005, 434 (7035): 864-870.CrossRefPubMed
45.
Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005, 434 (7035): 907-913.CrossRefPubMed
46.
Smedley D, Sidhar S, Birdsall S, Bennett D, Herlyn M, Cooper C, Shipley J: Characterization of chromosome 1 abnormalities in malignant melanomas. Genes Chromosomes Cancer. 2000, 28 (1): 121-125.CrossRefPubMed
47.
Gillanders E, Juo SH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D, Sood R, Park N, Faruque M, Markey C, Kefford RF, Palmer J, Bergman W, Bishop DT, Tucker MA, Bressac-de Paillerets B, Hansson J, Stark M, Gruis N, Bishop JN, Goldstein AM, Bailey-Wilson JE, Mann GJ, Hayward N, Trent J: Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet. 2003, 73 (2): 301-313.CrossRefPubMedPubMedCentral
48.
Walker GJ, Indsto JO, Sood R, Faruque MU, Hu P, Pollock PM, Duray P, Holland EA, Brown K, Kefford RF, Trent JM, Mann GJ, Hayward NK: Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval. Genes Chromosomes Cancer. 2004, 41 (1): 56-64.CrossRefPubMed
49.
Oegema K, Savoian MS, Mitchison TJ, Field CM: Functional analysis of a human homologue of the Drosophila actin binding protein anillin suggests a role in cytokinesis. J Cell Biol. 2000, 150 (3): 539-552.CrossRefPubMedPubMedCentral
50.
Stros M, Ozaki T, Bacikova A, Kageyama H, Nakagawara A: HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem. 2002, 277 (9): 7157-7164.CrossRefPubMed
51.
Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med. 2003, 197 (11): 1537-1549.CrossRefPubMedPubMedCentral
52.
de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E: Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003, 100 (19): 10972-10976.CrossRefPubMedPubMedCentral
53.
Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS, Shagoury JK, Bo-Abbas Y, Kuohung W, Schwinof KM, Hendrick AG, Zahn D, Dixon J, Kaiser UB, Slaugenhaupt SA, Gusella JF, O'Rahilly S, Carlton MB, Crowley WF, Aparicio SA, Colledge WH: The GPR54 gene as a regulator of puberty. N Engl J Med. 2003, 349 (17): 1614-1627.CrossRefPubMed
54.
Cheung CC, Thornton JE, Kuijper JL, Weigle DS, Clifton DK, Steiner RA: Leptin is a metabolic gate for the onset of puberty in the female rat. Endocrinology. 1997, 138 (2): 855-858.CrossRefPubMed
55.
Smith JT, Acohido BV, Clifton DK, Steiner RA: KiSS-1 neurones are direct targets for leptin in the ob/ob mouse. J Neuroendocrinol. 2006, 18 (4): 298-303.CrossRefPubMed
56.
Bilban M, Ghaffari-Tabrizi N, Hintermann E, Bauer S, Molzer S, Zoratti C, Malli R, Sharabi A, Hiden U, Graier W, Knofler M, Andreae F, Wagner O, Quaranta V, Desoye G: Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci. 2004, 117 (Pt 8): 1319-1328.CrossRefPubMed
57.
Xu G, Guimond MJ, Chakraborty C, Lala PK: Control of proliferation, migration, and invasiveness of human extravillous trophoblast by decorin, a decidual product. Biol Reprod. 2002, 67 (2): 681-689.CrossRefPubMed
58.
Vuillermoz B, Khoruzhenko A, D'Onofrio MF, Ramont L, Venteo L, Perreau C, Antonicelli F, Maquart FX, Wegrowski Y: The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res. 2004, 296 (2): 294-306.CrossRefPubMed
59.
Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000, 406 (6795): 536-540.CrossRefPubMed
60.
Dissanayake SK, Wade M, Johnson CE, O'Connell MP, Leotlela PD, French AD, Shah KV, Hewitt KJ, Rosenthal DT, Indig FE, Jiang Y, Nickoloff BJ, Taub DD, Trent JM, Moon RT, Bittner M, Weeraratna AT: The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem. 2007, 282 (23): 17259-17271.CrossRefPubMedPubMedCentral
61.
Kao YR, Shih JY, Wen WC, Ko YP, Chen BM, Chan YL, Chu YW, Yang PC, Wu CW, Roffler SR: Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin Cancer Res. 2003, 9 (7): 2807-2816.PubMed
62.
Gonzalez AM, Gonzales M, Herron GS, Nagavarapu U, Hopkinson SB, Tsuruta D, Jones JC: Complex interactions between the laminin alpha 4 subunit and integrins regulate endothelial cell behavior in vitro and angiogenesis in vivo. Proc Natl Acad Sci U S A. 2002, 99 (25): 16075-16080.CrossRefPubMedPubMedCentral
63.
French J, Stirling R, Walsh M, Kennedy HD: The expression of Ras-GTPase activating protein SH3 domain-binding proteins, G3BPs, in human breast cancers. Histochem J. 2002, 34 (5): 223-231.CrossRefPubMed
64.
Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M: Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol. 2003, 40 (2-4): 109-123.CrossRefPubMed
65.
Philip S, Kundu GC: Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem. 2003, 278 (16): 14487-14497.CrossRefPubMed
66.
Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S: MHC antigens in human melanomas. Semin Cancer Biol. 1991, 2 (1): 35-45.PubMed
67.
Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S, Chen Y, Bittner M, Strausberg RL, Riggins GJ, Wagner U, Kallioniemi OP, Trent JM, Morin PJ, Meltzer PS: Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene. 2004, 23 (12): 2264-2274.CrossRefPubMed
68.
Bernsen MR, Hakansson L, Gustafsson B, Krysander L, Rettrup B, Ruiter D, Hakansson A: On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases. Br J Cancer. 2003, 88 (3): 424-431.CrossRefPubMedPubMedCentral
69.
Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA, Rodriguez-Peralto JL: Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol. 2004, 164 (1): 193-203.CrossRefPubMedPubMedCentral
70.
Altomonte M, Fonsatti E, Visintin A, Maio M: Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?. Oncogene. 2003, 22 (42): 6564-6569.CrossRefPubMed
71.
Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco MC, Chiarion-Sileni V, Mocellin S, Rossi CR, Bicciato S, Wang E, Marincola FM, Zanovello P: A gene expression signature associated with survival in metastatic melanoma. J Transl Med. 2006, 4: 50-CrossRefPubMedPubMedCentral
72.
Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT, Sirigu P: The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer. 2005, 104 (6): 1246-1254.CrossRefPubMed
73.
van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, Ferrone S: Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res. 1988, 48 (4): 1019-1025.PubMed
74.
Rangel LB, Agarwal R, Sherman-Baust CA, Mello-Coelho V, Pizer ES, Ji H, Taub DD, Morin PJ: Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers. Cancer Biol Ther. 2004, 3 (10): 1021-1027.CrossRefPubMed
75.
Shy ME, Hobson G, Jain M, Boespflug-Tanguy O, Garbern J, Sperle K, Li W, Gow A, Rodriguez D, Bertini E, Mancias P, Krajewski K, Lewis R, Kamholz J: Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Ann Neurol. 2003, 53 (3): 354-365.CrossRefPubMedPubMedCentral
76.
Skubitz KM, Skubitz AP: Differential gene expression in uterine leiomyoma. J Lab Clin Med. 2003, 141 (5): 297-308.CrossRefPubMed
77.
Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson KL, Phillips DJ, Herlyn M, Schadendorf D, Dummer R: Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 2006, 19 (4): 290-302.CrossRefPubMed
78.
Stolt CC, Rehberg S, Ader M, Lommes P, Riethmacher D, Schachner M, Bartsch U, Wegner M: Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor Sox10. Genes Dev. 2002, 16 (2): 165-170.CrossRefPubMedPubMedCentral
79.
Potterf SB, Furumura M, Dunn KJ, Arnheiter H, Pavan WJ: Transcription factor hierarchy in Waardenburg syndrome: regulation of MITF expression by SOX10 and PAX3. Hum Genet. 2000, 107 (1): 1-6.CrossRefPubMed
80.
Levy C, Khaled M, Fisher DE: MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 2006
81.
Steingrimsson E, Copeland NG, Jenkins NA: Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet. 2004, 38: 365-411.CrossRefPubMed
82.
Loercher AE, Tank EM, Delston RB, Harbour JW: MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol. 2005, 168 (1): 35-40.CrossRefPubMedPubMedCentral
83.
Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, Denat L, Larue L, Goding CR: Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature. 2005, 433 (7027): 764-769.CrossRefPubMed
84.
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005, 436 (7047): 117-122.CrossRefPubMed
85.
Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, Fisher DE: Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell. 2004, 6 (6): 565-576.CrossRefPubMed
86.
Busca R, Berra E, Gaggioli C, Khaled M, Bille K, Marchetti B, Thyss R, Fitsialos G, Larribere L, Bertolotto C, Virolle T, Barbry P, Pouyssegur J, Ponzio G, Ballotti R: Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol. 2005, 170 (1): 49-59.CrossRefPubMedPubMedCentral
87.
McGill GG, Haq R, Nishimura EK, Fisher DE: c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem. 2006, 281 (15): 10365-10373.CrossRefPubMed
88.
Gaggioli C, Robert G, Bertolotto C, Bailet O, Abbe P, Spadafora A, Bahadoran P, Ortonne JP, Baron V, Ballotti R, Tartare-Deckert S: Tumor-Derived Fibronectin Is Involved in Melanoma Cell Invasion and Regulated by V600E B-Raf Signaling Pathway. J Invest Dermatol. 2006
89.
White JM: ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol. 2003, 15 (5): 598-606.CrossRefPubMed
90.
Sahoo S, Brickley DR, Kocherginsky M, Conzen SD: Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer. Eur J Cancer. 2005, 41 (17): 2754-2759.CrossRefPubMed
91.
Chen C, Li M, Chai H, Yang H, Fisher WE, Yao Q: Roles of neuropilins in neuronal development, angiogenesis, and cancers. World J Surg. 2005, 29 (3): 271-275.CrossRefPubMed
92.
Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, Wu T, Niinobe M, Yoshikawa K, Hannigan GE, Halaban R: Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 2004, 64 (15): 5270-5282.CrossRefPubMed
93.
de Souza GA, Godoy LM, Teixeira VR, Otake AH, Sabino A, Rosa JC, Dinarte AR, Pinheiro DG, Silva WA, Eberlin MN, Chammas R, Greene LJ: Proteomic and SAGE profiling of murine melanoma progression indicates the reduction of proteins responsible for ROS degradation. Proteomics. 2006, 6 (5): 1460-1470.CrossRefPubMed
94.
Bernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, Polvinen K, Everett AD, Fukasawa K, Norris DA, Ahn NG, Resing KA: Functional proteomic analysis of melanoma progression. Cancer Res. 2003, 63 (20): 6716-6725.PubMed
Metadata
Title
Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets
Authors
Josane F Sousa
Enilza M Espreafico
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-19

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR

Research article

Expression of TRPC6 channels in human epithelial breast cancer cells

Research article

Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases

Research article

Important prognostic factors for the long-term survival of lung cancer subjects in Taiwan

Research article

Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer

Research article

Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits